Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ASC 41

Next Previous
Drug Profile

ASC 41

Alternative Names: ASC-41

Latest Information Update: 12 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ascletis
  • Developer Gannex Pharma
  • Class Antihyperlipidaemics; Hepatoprotectants; Obesity therapies; Small molecules
  • Mechanism of Action Thyroid hormone receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis
  • No development reported Non-alcoholic fatty liver disease

Most Recent Events

  • 12 Jun 2024 Updated efficacy data from a phase II trial in Nonalcoholic Steatohepatitis presented at European Association for the Study of the Liver Congress 2024 (EASL-2024)
  • 10 Jun 2024 Gannex Pharma has patent protection for ASC 41 tablet formulation in the US
  • 10 Jun 2024 Efficacy and adverse events data from a phase II trial in Nonalcoholic Steatohepatitis released by Gannex Pharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top